Literature DB >> 30247214

Regional citrate anticoagulation for continuous renal replacement therapy.

Detlef Kindgen-Milles1, Timo Brandenburger, Thomas Dimski.   

Abstract

PURPOSE OF REVIEW: The delivery of an effective dialysis dose in continuous renal replacement therapy (CRRT) depends on adequate anticoagulation of the extracorporeal circuit. In most patients, either systemic heparin anticoagulation (SHA) or regional citrate anticoagulation (RCA) is used. This review will outline the basics and rationale of RCA and summarize data on safety and efficacy of both techniques. RECENT
FINDINGS: The basic principle of RCA is to reduce the level of ionized calcium in the extracorporeal circuit via infusion of citrate. This way, effective anticoagulation restricted to the extracorporeal circuit is achieved. SHA and RCA were compared in a variety of studies. RCA significantly prolonged filter lifetime, reduced bleeding complications and provided excellent control of uremia and acid-base status. RCA was also safe in the majority of patients with impaired liver function, whereas caution must be exerted in those with severe multiorgan failure and persistent hyperlactatemia.
SUMMARY: RCA per se is safe and effective for anticoagulation of CRRT. Compared to SHA, efficacy of anticoagulation is improved and adverse effects are reduced. RCA can be recommended as the anticoagulation mode of choice for CRRT in most ICU patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30247214     DOI: 10.1097/MCC.0000000000000547

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  7 in total

1.  Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study.

Authors:  Doug W Gould; James Doidge; M Zia Sadique; Mark Borthwick; Robert Hatch; Fergus J Caskey; Lui Forni; Robert F Lawrence; Clare MacEwen; Marlies Ostermann; Paul R Mouncey; David A Harrison; Kathryn M Rowan; J Duncan Young; Peter J Watkinson
Journal:  Health Technol Assess       Date:  2022-02       Impact factor: 4.014

2.  Transient blood thinning during extracorporeal blood purification via the inactivation of coagulation factors by hydrogel microspheres.

Authors:  Xin Song; Haifeng Ji; Yupei Li; Yuqin Xiong; Li Qiu; Rui Zhong; Meng Tian; Jayachandran N Kizhakkedathu; Baihai Su; Qiang Wei; Weifeng Zhao; Changsheng Zhao
Journal:  Nat Biomed Eng       Date:  2021-01-25       Impact factor: 25.671

3.  Electrolyte monitoring during regional citrate anticoagulation in continuous renal replacement therapy.

Authors:  C Warnar; E Faber; P A Katinakis; T Schermer; P E Spronk
Journal:  J Clin Monit Comput       Date:  2021-05-15       Impact factor: 1.977

4.  Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study.

Authors:  Yan Yu; Ming Bai; Zhang Wei; Lijuan Zhao; Yangping Li; Feng Ma; Shiren Sun
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

5.  Feasibility and efficacy of modified fixed citrate concentration protocol using only commercial preparations in critically ill patients: a prospective cohort study with a historical control group.

Authors:  Yan Shi; Han-Yu Qin; Jin-Min Peng; Xiao-Yun Hu; Bin Du
Journal:  BMC Anesthesiol       Date:  2021-03-30       Impact factor: 2.217

6.  Double Pump Sequential Constant Citrate Anticoagulation in General Hemodialysis.

Authors:  Li Tang; Jiali Zhang; Qijun Cheng; Jie Li; Ling Zhou; Li Wang; Changbin Liao
Journal:  Appl Bionics Biomech       Date:  2022-07-26       Impact factor: 1.664

7.  Early warning of citric acid overdose and timely adjustment of regional citrate anticoagulation based on machine learning methods.

Authors:  Huan Chen; Yingying Ma; Na Hong; Hao Wang; Longxiang Su; Chun Liu; Jie He; Huizhen Jiang; Yun Long; Weiguo Zhu
Journal:  BMC Med Inform Decis Mak       Date:  2021-07-30       Impact factor: 2.796

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.